This PubMed record documents a peer‑reviewed article published in Nature Communications in 2026 titled Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. The citation on PubMed lists the publication date as 2026 Oct 8 and the journal pagination/identifier as 17(1):10608.
The PubMed entry functions primarily as a bibliographic record: it provides the article title, author list, affiliations, journal name, DOI (10.1038/s41467-026-78312-3) and PubMed identifier (PMID 42844286). The record also exposes the standard PubMed navigation elements (Title & authors, Abstract, Conflict of interest statement, References, MeSH terms, Substances, Grants and funding), but the excerpt available here does not include the article abstract or the manuscript text itself.
The article lists a multi‑author team led by Semjon Willier as first author, followed by numerous coauthors. The author group represents a broad collaboration across multiple German research and clinical centers. Reported affiliations include, among others:
Affiliation detail indicates a multi‑disciplinary team spanning pediatric oncology, immunology, cellular immunotherapy, pathology and translational cancer research centers.
Key bibliographic identifiers shown in the PubMed entry:
The PubMed record also provides standard site functionality such as citation export, saving to collections, emailing the citation, and links to full article metadata on the publisher site via DOI.
The article title indicates the manuscript addresses targeting CD28 on T lineage malignancies using chimeric antigen receptor (CAR) T cells. From the title alone, the work likely involves preclinical or translational investigation into CD28 as a target antigen and the design, testing or evaluation of CAR T cells directed against CD28 in the context of T‑cell or T‑lineage cancers.
Importantly, the excerpted PubMed content does not include the abstract, methods, results, or conclusions. Therefore this summary does not attempt to infer or report experimental findings, efficacy, safety data, study design, or clinical recommendations — none of which are provided in the supplied source text.
The PubMed page layout lists typical sections where additional manuscript information would appear (e.g., Abstract, Conflict of interest statement, References, MeSH terms, Substances, Grants and funding). In the content supplied here these sections are present as navigation links, but their substantive contents (for example the abstract text, detailed conflict of interest disclosures, the reference list, indexed MeSH headings or named grant support) are not included in the provided excerpt.
Because the supplied record excerpt lacks the abstract and manuscript body, specific details such as the experimental approach, cohort characteristics (if clinical), preclinical models used, primary and secondary endpoints, numerical outcomes, statistical analyses, and authors' interpretations are not reported here.
To review the full article text, primary data, figures, and supplementary material, consult the publisher page or the full PubMed record using the DOI or PMID given above. Available access routes include:
The PubMed entry also provides citation export and collection tools that can assist with retrieving the full reference for literature management or for requesting the document via institutional interlibrary loan if direct access is restricted.
The PubMed navigation indicates that the article page contains sections for conflict of interest statements, references, MeSH terms, substances and grants. The excerpt provided here does not include those detailed entries, so their contents are not reported. For complete disclosure statements, funding sources, and the indexed subject headings that characterize the manuscript, readers should consult the full PubMed record and the publisher version of the article.
Conclusion
This PubMed record confirms a 2026 Nature Communications article titled "Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells," authored by a multi‑institutional German research team and indexed under PMID 42844286 with DOI 10.1038/s41467-026-78312-3. The supplied source excerpt does not include the abstract or manuscript text, so no study specifics or outcomes are available here. To evaluate the study design, data and conclusions, please access the full article via DOI or the PubMed entry.